AbbVie 2014 Annual Report Download - page 7

13NOV201221352027
ITEM 1. BUSINESS
.....................................................................................................................................................................................................................................................................................................................................................
Separation from Abbott Laboratories
AbbVie(1) was incorporated in Delaware on April 10, 2012. On January 1, 2013, AbbVie became an
independent company as a result of the distribution by Abbott Laboratories (Abbott) of 100 percent of the
outstanding common stock of AbbVie to Abbott’s shareholders. AbbVie’s common stock began trading
‘‘regular-way’’ under the ticker symbol ‘‘ABBV’’ on the New York Stock Exchange on January 2, 2013.
Overview
AbbVie is a global, research-based biopharmaceutical company. AbbVie develops and markets advanced
therapies that address some of the world’s most complex and serious diseases. AbbVie’s products are
focused on treating conditions such as chronic autoimmune diseases, including rheumatoid arthritis,
psoriasis, and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis;
thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis;
and other health conditions such as low testosterone. AbbVie also has a pipeline of promising new
medicines, including more than 30 compounds or indications in Phase 2 or Phase 3 development across
such important medical specialties as immunology, virology/liver disease, oncology, renal disease,
neurological diseases and women’s health.
Segments
AbbVie operates in one business segment—pharmaceutical products. Incorporated herein by reference
is Note 15 entitled ‘‘Segment and Geographic Area Information’’ of the Notes to Consolidated Financial
Statements included under Item 8, ‘‘Financial Statements and Supplementary Data’’ and the sales
information related to HUMIRA included under Item 7, ‘‘Management’s Discussion and Analysis of Financial
Condition and Results of Operations—Results of Operations.’’
Products
AbbVie’s portfolio of products includes a broad line of therapies that address some of the world’s most
complex and serious diseases.
HUMIRA. HUMIRA is a biologic therapy administered as a subcutaneous injection. It is approved to
treat the following autoimmune diseases in the United States, Canada, and Mexico (collectively, North
America), and in the European Union:
Condition Principal Markets
Rheumatoid arthritis (moderate to severe) North America, European Union
Psoriatic arthritis North America, European Union
Ankylosing spondylitis North America, European Union
Crohn’s disease (moderate to severe) North America, European Union
Plaque psoriasis (moderate to severe) North America, European Union
Juvenile idiopathic arthritis North America, European Union
Ulcerative colitis (moderate to severe) United States, European Union
Axial spondyloarthropathy United States, European Union
Pediatric Crohn’s disease (severe) United States, European Union
Pediatric enthesitis-related arthritis European Union
(1) As used throughout the text of this report on Form 10-K, the term ‘‘AbbVie’’ refers to AbbVie Inc., a
Delaware corporation, or AbbVie Inc. and its consolidated subsidiaries, as the context requires.
2014 Form 10-K 1
PART I